The stock price of Viking Therapeutics Inc (NASDAQ: VKTX) has dropped by -3.39 compared to previous close of 76.97. Despite this, the company has seen a fall of -1.40% in its stock price over the last five trading days. InvestorPlace reported 2024-05-02 that According to Harvard University, about two-thirds of United States adults are “overweight or obese,” while 36% are obese. And the university predicts that, at the current rate, about 50% of Americans will be obese by 2030.
Is It Worth Investing in Viking Therapeutics Inc (NASDAQ: VKTX) Right Now?
Moreover, the 36-month beta value for VKTX is 1.11. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VKTX is 101.35M and currently, short sellers hold a 11.00% of that float. On May 06, 2024, VKTX’s average trading volume was 6.47M shares.
VKTX’s Market Performance
The stock of Viking Therapeutics Inc (VKTX) has seen a -1.40% decrease in the past week, with a -2.73% drop in the past month, and a 201.55% gain in the past quarter. The volatility ratio for the week is 6.11%, and the volatility levels for the past 30 days are at 5.68% for VKTX. The simple moving average for the past 20 days is 5.44% for VKTX’s stock, with a 145.91% simple moving average for the past 200 days.
Analysts’ Opinion of VKTX
Many brokerage firms have already submitted their reports for VKTX stocks, with Oppenheimer repeating the rating for VKTX by listing it as a “Outperform.” The predicted price for VKTX in the upcoming period, according to Oppenheimer is $138 based on the research report published on March 26, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see VKTX reach a price target of $110. The rating they have provided for VKTX stocks is “Buy” according to the report published on March 07th, 2024.
Oppenheimer gave a rating of “Outperform” to VKTX, setting the target price at $116 in the report published on February 28th of the current year.
VKTX Trading at 2.85% from the 50-Day Moving Average
After a stumble in the market that brought VKTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.20% of loss for the given period.
Volatility was left at 5.68%, however, over the last 30 days, the volatility rate increased by 6.11%, as shares sank -0.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +101.42% upper at present.
During the last 5 trading sessions, VKTX fell by -0.06%, which changed the moving average for the period of 200-days by +395.87% in comparison to the 20-day moving average, which settled at $70.50. In addition, Viking Therapeutics Inc saw 299.58% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VKTX starting from ZANTE GREG, who sale 66,756 shares at the price of $74.69 back on May 03 ’24. After this action, ZANTE GREG now owns 174,854 shares of Viking Therapeutics Inc, valued at $4,986,008 using the latest closing price.
Mancini Marianna, the Chief Operating Officer of Viking Therapeutics Inc, sale 281,425 shares at $78.66 during a trade that took place back on May 01 ’24, which means that Mancini Marianna is holding 348,508 shares at $22,136,474 based on the most recent closing price.
Stock Fundamentals for VKTX
Current profitability levels for the company are sitting at:
- -262.3 for the present operating margin
- 0.33 for the gross margin
The net margin for Viking Therapeutics Inc stands at -214.95. The total capital return value is set at -0.12. Equity return is now at value -17.55, with -16.76 for asset returns.
Based on Viking Therapeutics Inc (VKTX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -46.46. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -1906.05.
Currently, EBITDA for the company is -100.53 million with net debt to EBITDA at 1.7. When we switch over and look at the enterprise to sales, we see a ratio of 18408.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 29.48.
Conclusion
To wrap up, the performance of Viking Therapeutics Inc (VKTX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
